269 related articles for article (PubMed ID: 34745934)
1. A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
Zhu M; Liang C; Zhang F; Zhu L; Chen D
Front Oncol; 2021; 11():690336. PubMed ID: 34745934
[TBL] [Abstract][Full Text] [Related]
2. Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics.
Sheng DL; Shen XG; Shi ZT; Chang C; Li JW
Eur Radiol; 2022 Oct; 32(10):6575-6587. PubMed ID: 35759017
[TBL] [Abstract][Full Text] [Related]
3. Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Chen L; Kong X; Huang S; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
Front Immunol; 2022; 13():831848. PubMed ID: 35320931
[TBL] [Abstract][Full Text] [Related]
4. Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.
Qian B; Yang J; Zhou J; Hu L; Zhang S; Ren M; Qu X
Front Endocrinol (Lausanne); 2022; 13():955250. PubMed ID: 36060977
[TBL] [Abstract][Full Text] [Related]
5. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
6. A CT-based deep learning radiomics nomogram for predicting the response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A multicenter cohort study.
Cui Y; Zhang J; Li Z; Wei K; Lei Y; Ren J; Wu L; Shi Z; Meng X; Yang X; Gao X
EClinicalMedicine; 2022 Apr; 46():101348. PubMed ID: 35340629
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the impact of residual tumors at different sites post-neoadjuvant chemotherapy on prognosis in breast cancer patients and development of a disease-free survival prediction model.
Yang H; Ruan Y; Sun Y; Wang P; Qiao J; Wang C; Liu Z
Ther Adv Med Oncol; 2024; 16():17588359241249578. PubMed ID: 38736552
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a prognostic nomogram for patients with triple-negative breast cancer with histology of infiltrating duct carcinoma.
Jing N; Ma MW; Gao XS; Liu JT; Gu XB; Zhang M; Zhao B; Wang Y; Wang XL; Jia HX
Ann Transl Med; 2020 Nov; 8(21):1447. PubMed ID: 33313192
[TBL] [Abstract][Full Text] [Related]
9. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Marmé F; Solbach C; Michel L; Schneeweiss A; Blohmer JU; Huober J; Fasching PA; Jackisch C; Nekljudova V; Link T; Rhiem K; Rey J; Denkert C; Hanusch C; Tesch H; Lederer B; Loibl S; Untch M
Eur J Cancer; 2021 Aug; 153():203-212. PubMed ID: 34186505
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy.
Chen L; Huang S; Liu Q; Kong X; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
Front Immunol; 2022; 13():849468. PubMed ID: 35669769
[TBL] [Abstract][Full Text] [Related]
11. Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc.
Cui J; Jiang H
Medicine (Baltimore); 2019 Oct; 98(40):e17370. PubMed ID: 31577739
[TBL] [Abstract][Full Text] [Related]
12. Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy.
Lai J; Wang H; Peng J; Chen P; Pan Z
Cancer Manag Res; 2018; 10():2347-2356. PubMed ID: 30122984
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.
Li Y; Chen Y; Zhao R; Ji Y; Li J; Zhang Y; Lu H
Eur Radiol; 2022 Mar; 32(3):1676-1687. PubMed ID: 34767068
[TBL] [Abstract][Full Text] [Related]
14. A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy.
Xia B; Wang H; Wang Z; Qian Z; Xiao Q; Liu Y; Shao Z; Zhou S; Chai W; You C; Gu Y
Front Genet; 2021; 12():783513. PubMed ID: 34868273
[No Abstract] [Full Text] [Related]
15. Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer.
Yang Y; Wang Y; Deng H; Tan C; Li Q; He Z; Wei W; Zhou E; Liu Q; Liu J
BMC Cancer; 2019 Jun; 19(1):541. PubMed ID: 31170946
[TBL] [Abstract][Full Text] [Related]
16. Development of a nomogram for predicting survival of breast cancer patients with neoadjuvant chemotherapy: a dynamic analysis for systemic inflammation response index.
Huang W; Xiong Z; Zhong W; Zhang C; Feng J; Wang X
Gland Surg; 2023 Nov; 12(11):1459-1474. PubMed ID: 38107499
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a prognostic nomogram for 2018 FIGO stages IB1, IB2, and IIA1 cervical cancer: a large multicenter study.
Chen X; Duan H; Liu P; Lin L; Ni Y; Li D; Dai E; Zhan X; Li P; Huo Z; Bin X; Lang J; Chen C
Ann Transl Med; 2022 Jan; 10(2):121. PubMed ID: 35282114
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
Xia LY; Hu QL; Zhang J; Xu WY; Li XS
World J Surg Oncol; 2020 Jun; 18(1):129. PubMed ID: 32539858
[TBL] [Abstract][Full Text] [Related]
19. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Model of D2 Radical Gastrectomy Combined with Neoadjuvant Chemotherapy for Gastric Cancer.
Wang G; Tan Y; Jiang Y; Liu J; Su Y; Sun Z; Liu B
Risk Manag Healthc Policy; 2023; 16():1259-1271. PubMed ID: 37456825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
